Minerva Neurosciences Inc
NERV4.040USD
+0.170+4.39%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
28.25MMarket Cap
LossP/E TTM
More Details of Minerva Neurosciences Inc Company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Minerva Neurosciences Inc Info
Ticker SymbolNERV
Company nameMinerva Neurosciences Inc
IPO dateJun 25, 2014
CEOLuthringer (Remy)
Number of employees8
Security typeOrdinary Share
Fiscal year-endJun 25
Address1601 Trapelo Road
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16176007373
Websitehttps://www.minervaneurosciences.com/
Ticker SymbolNERV
IPO dateJun 25, 2014
CEOLuthringer (Remy)
Company Executives of Minerva Neurosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Mr. Jan G. van Heek
Mr. Jan G. van Heek
Independent Director
Independent Director
--
--
Dr. Fouzia Laghrissi-Thode, M.D.
Dr. Fouzia Laghrissi-Thode, M.D.
Independent Director
Independent Director
--
--
Mr. Frederick Ahlholm, CPA
Mr. Frederick Ahlholm, CPA
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Dr. Inderjit Kaul, M.D.
Dr. Inderjit Kaul, M.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Mr. Jan G. van Heek
Mr. Jan G. van Heek
Independent Director
Independent Director
--
--
Dr. Fouzia Laghrissi-Thode, M.D.
Dr. Fouzia Laghrissi-Thode, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
19.32%
Boehringer Ingelheim International GmbH
18.23%
The Vanguard Group, Inc.
3.60%
Luthringer (Remy)
2.64%
Renaissance Technologies LLC
1.67%
Other
54.53%
Shareholders
Shareholders
Proportion
Federated Hermes Global Investment Management Corp.
19.32%
Boehringer Ingelheim International GmbH
18.23%
The Vanguard Group, Inc.
3.60%
Luthringer (Remy)
2.64%
Renaissance Technologies LLC
1.67%
Other
54.53%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
20.89%
Corporation
18.23%
Investment Advisor
5.49%
Individual Investor
4.02%
Hedge Fund
2.01%
Research Firm
0.11%
Other
49.25%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
42
1.98M
28.26%
-175.70K
2025Q2
48
3.52M
50.35%
-247.08K
2025Q1
50
3.52M
50.36%
-205.49K
2024Q4
51
3.66M
52.27%
-624.23K
2024Q3
54
3.69M
57.40%
+418.43K
2024Q2
57
3.64M
56.76%
+303.74K
2024Q1
68
3.68M
57.33%
+358.05K
2023Q4
70
4.01M
62.11%
+650.59K
2023Q3
86
4.01M
62.11%
+311.12K
2023Q2
109
3.95M
71.07%
+754.34K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Federated Hermes Global Investment Management Corp.
1.35M
19.32%
--
--
Jun 30, 2025
Boehringer Ingelheim International GmbH
1.27M
18.23%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
252.06K
3.6%
--
--
Jun 30, 2025
Luthringer (Remy)
184.82K
2.64%
--
--
Mar 31, 2025
Renaissance Technologies LLC
111.00K
1.59%
-3.10K
-2.71%
Jun 30, 2025
Geode Capital Management, L.L.C.
75.63K
1.08%
-1.11K
-1.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
72.67K
1.04%
--
--
Jun 30, 2025
Race (Geoffrey)
51.32K
0.73%
--
--
Mar 31, 2025
Apella Wealth
20.94K
0.3%
+314.00
+1.52%
Jun 30, 2025
Kupfer (David J)
23.94K
0.34%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Date
Type
Ratio
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
Jun 17, 2022
Merger
8→1
FAQs
Who are the top five shareholders of Minerva Neurosciences Inc?
The top five shareholders of Minerva Neurosciences Inc are:
Federated Hermes Global Investment Management Corp. holds 1.35M shares, accounting for 19.32% of the total shares.
Boehringer Ingelheim International GmbH holds 1.27M shares, accounting for 18.23% of the total shares.
The Vanguard Group, Inc. holds 252.06K shares, accounting for 3.60% of the total shares.
Luthringer (Remy) holds 184.82K shares, accounting for 2.64% of the total shares.
Renaissance Technologies LLC holds 111.00K shares, accounting for 1.59% of the total shares.
Federated Hermes Global Investment Management Corp. holds 1.35M shares, accounting for 19.32% of the total shares.
Boehringer Ingelheim International GmbH holds 1.27M shares, accounting for 18.23% of the total shares.
The Vanguard Group, Inc. holds 252.06K shares, accounting for 3.60% of the total shares.
Luthringer (Remy) holds 184.82K shares, accounting for 2.64% of the total shares.
Renaissance Technologies LLC holds 111.00K shares, accounting for 1.59% of the total shares.
What are the top three shareholder types of Minerva Neurosciences Inc?
The top three shareholder types of Minerva Neurosciences Inc are:
Federated Hermes Global Investment Management Corp.
Boehringer Ingelheim International GmbH
The Vanguard Group, Inc.
Federated Hermes Global Investment Management Corp.
Boehringer Ingelheim International GmbH
The Vanguard Group, Inc.
How many institutions hold shares of Minerva Neurosciences Inc (NERV)?
As of 2025Q3, 42 institutions hold shares of Minerva Neurosciences Inc, with a combined market value of approximately 1.98M, accounting for 28.26% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.08%.
What is the biggest source of revenue for Minerva Neurosciences Inc?
In FY2021, the -- business generated the highest revenue for Minerva Neurosciences Inc, amounting to -- and accounting for --% of total revenue.
